***Background.*** Pneumococcal 13-valent conjugate vaccine (PCV13) was licensed for use among adults \>= 50 years old in 2012. Currently routine PCV13 use among US adults is not recommended. Efficacy of PCV13 against invasive pneumococcal disease (IPD) and community acquired pneumococcal pneumonia (CAP) among adults \>= 65 years has recently been demonstrated in the CAPITA randomized clinical trial. We evaluated potential public health impact of PCV13 use among US adults \>= 65 years on IPD and CAP in a setting of routine polysaccharide vaccine use and indirect effects observed following two years of PCV13 use among children.

***Methods.*** We used 2012 IPD incidence from Active Bacterial Core surveillance and US Census Bureau denominators to estimate the number of PCV13 type IPD cases among adults \>= 65 years in the US. We used published estimates of the burden of CAP and the proportion of CAP due to PCV13 serotypes among adults \>= 65 years. We applied PCV13 efficacy estimates against PCV13-type IPD and CAP reported in CAPITA to the estimated burden of PCV13-type IPD and CAP to obtain the expected number of cases prevented through routine PCV13 use among adults \>= 65 years old. We considered a range of 60% to 90% for PCV13 coverage. We estimated number needed to vaccinate (NNV) to prevent a single case of IPD and CAP as 1/(incidence pre-PCV13 minus incidence post PCV13).

***Results.*** Assuming 60% PCV13 coverage and no further reduction in PCV13-type IPD or CAP through indirect effects, an estimated 1,600 cases of IPD (range 900 to 2,000) and 32,700 cases of inpatient CAP (18,000 to 40,000) would be prevented annually in the US. Continued reductions in PCV13-type disease through indirect effects would reduce the expected direct benefits of PCV13 use among adults. If PCV13 coverage in adults is increased to 90%, the number of cases prevented annually would increase to 2,500 (1,400 to 3,000) for IPD and to 49,000 (27,000 to 59,300) for CAP. An estimated 27,800 (22,700-50,000) adults \>= 65 years old would need to be vaccinated to prevent a single case of PCV13-type IPD; NNV for PCV13-type CAP was 1,620 (1,110 - 5,130).

***Conclusion.*** Routine PCV13 use among adults \>= 65 years old can lead to substantial reductions in the remaining vaccine-preventable burden of IPD and pneumonia. Improving pneumococcal vaccine coverage among adults will further increase these benefits.
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